Buzz Stocks: Best Buy, bluebird bio, and Omnicare

Today's stocks to watch include Best Buy Co Inc (NYSE:BBY), bluebird bio Inc (NASDAQ:BLUE), and Omnicare, Inc. (NYSE:OCR)

May 21, 2015 at 9:30 AM
facebook twitter linkedin


Heading into a jam-packed session on the economic front, U.S. stocks are pointed lower. Among the equities in focus are electronics retailer Best Buy Co Inc (NYSE:BBY), biotech concern bluebird bio Inc (NASDAQ:BLUE)​, and healthcare services provider Omnicare, Inc. (NYSE:OCR).

  • BBY is getting a lift this morning from impressive first-quarter numbers. Shares of the retailer are 8% higher in pre-market trading after closing yesterday at $33.78. While 2015 has been tough on Best Buy Co Inc, the stock is a longer-term success story, adding over 33% in the past 12 months. In recent months, though, options traders have grown pessimistic. The stock's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.12 is only 8 percentage points from an annual bearish peak.

  • BLUE is set to do even better out of the gate, as the stock is up 11.6% ahead of the open -- and on pace for a record high -- after the company announced a patient with sickle cell disease was treated successfully using its gene therapy. It's not like bluebird bio Inc needed to boost shareholder morale. The equity closed yesterday at $165.71, compared to a closing price of just $23.30 this time last year. This dominant technical performance is likely part of the reason all nine brokerage firms tracking BLUE say it's a "strong buy." Also, its consensus 12-month price target is $201.13 -- a 21.4% premium to current levels, and territory never before seen.

  • OCR is sporting a 1.3% lead in electronic trading, due to news the company will be purchased by CVS Health Corp (NYSE:CVS) for nearly $13 billion. Omnicare, Inc. has been strong on the charts, outdoing the S&P 500 Index (SPX) by almost 20 percentage points over the past three months. In fact, the security touched an all-time high of $95.09 yesterday, before settling at $94.63. Put buying has been more popular than normal, nonetheless. OCR's 50-day ISE/CBOE/PHLX put/call volume ratio of 0.17 is higher than 82% of readings from the past year.
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners